Comparative Pharmacology
Head-to-head clinical analysis: FAMCICLOVIR versus TRIFLURIDINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FAMCICLOVIR versus TRIFLURIDINE.
FAMCICLOVIR vs TRIFLURIDINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Famciclovir is a prodrug of penciclovir, which inhibits viral DNA polymerase by competing with deoxyguanosine triphosphate, thus inhibiting viral DNA replication. It has activity against herpes simplex virus (HSV-1, HSV-2), varicella-zoster virus (VZV), and Epstein-Barr virus (EBV).
Trifluridine is a thymidine analog that inhibits thymidylate synthase and incorporates into DNA, leading to DNA damage and cell death.
500 mg orally three times daily for 7 days for herpes zoster; 125 mg twice daily for 5 days for recurrent genital herpes; 250 mg three times daily for 7 days for first-episode genital herpes; 500 mg twice daily for 7 days for recurrent herpes labialis.
Topical: Apply one drop to affected eye every 2 hours while awake (maximum 9 drops/day) until re-epithelialization, then one drop every 4 hours for 7 days. Ophthalmic solution 1%.
None Documented
None Documented
Clinical Note
moderateTrifluridine + Digoxin
"Trifluridine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateTrifluridine + Digitoxin
"Trifluridine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateTrifluridine + Deslanoside
"Trifluridine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateTrifluridine + Acetyldigitoxin
"Trifluridine may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life of penciclovir is 2-3 hours in healthy adults, prolonged to 3-6 hours in hepatic impairment and >20 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
The terminal elimination half-life of trifluridine is approximately 12-18 hours. This prolonged half-life supports twice-daily dosing and provides sustained exposure for antiviral activity.
Renal elimination: ~60% as penciclovir (active metabolite) and <10% as unchanged famciclovir; biliary/fecal: <5%; the remainder is metabolized to inactive compounds.
Renal excretion accounts for approximately 40-50% of the administered dose, primarily as the inactive metabolite 5-trifluorothymidine. Fecal excretion is minimal (<5%). The remainder is eliminated via metabolic degradation.
Category A/B
Category C
Antiviral
Antiviral